A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 300 participants.
Also called NCT07754825
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 300 participants
- Registry
-
NCT07754825
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07754825. Randomized; double masking; primary purpose treatment. Start 2026-12-01 (anticipated); primary completion 2027-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic Stroke
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- LT3001 Drug:high dose
- Intervention (Drug)
- LT3001 Drug: low dose
- Intervention (Drug)
- Placebo
- Lead sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Record details
- Record id
cardio:ct-nct07754825- Content hash
97981eb52a1ec1e83daf5a6659a9b9d1bb04a9bafec33ada8b081eec72131988